For the quarter ending 2026-03-31, DNLI has $1,266,023K in assets. $339,925K in debts. $387,626K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 387,626 | 205,326 | 90,963 | 141,207 |
| Short-term marketable securities | 600,058 | 662,553 | 757,241 | 757,745 |
| Prepaid expenses and other current assets | 35,068 | 32,779 | 34,394 | 35,754 |
| Total current assets | 1,022,752 | 900,658 | 882,598 | 934,706 |
| Long-term marketable securities | 63,785 | 98,322 | 24,703 | 78,463 |
| Property and equipment, net | 51,728 | 52,402 | 53,732 | 58,717 |
| Finance lease right-of-use asset | 47,616 | 48,531 | 49,447 | 50,363 |
| Operating lease right-of-use asset | 17,922 | 19,002 | 20,035 | 21,022 |
| Intangible asset, net | 36,000 | - | - | - |
| Other non-current assets | 26,220 | 25,939 | 25,106 | 22,970 |
| Total assets | 1,266,023 | 1,144,854 | 1,055,621 | 1,166,241 |
| Accounts payable | 40,380 | 3,330 | 6,745 | 10,844 |
| Accrued compensation | - | - | 18,358 | 12,068 |
| Accrued clinical and other research and development costs | - | - | 23,355 | 23,379 |
| Accrued manufacturing costs | - | - | 5,002 | 9,028 |
| Operating lease liability, current | - | - | 9,164 | 8,871 |
| Deferred research and development funding liability, current | - | - | 22,580 | 19,861 |
| Other accrued costs and current liabilities | 69,776 | 95,021 | 4,942 | 7,006 |
| Total current liabilities | 110,156 | 98,351 | 90,146 | 91,057 |
| Operating lease liability, less current portion | 24,680 | 27,210 | 29,686 | 32,110 |
| Finance lease liability, less current portion | 5,508 | 5,532 | 5,554 | 5,577 |
| Deferred research funding and development liability, less current portion | - | - | 4,038 | 10,444 |
| Liability related to the revenue participation right agreement | 199,581 | - | - | - |
| Total liabilities | 339,925 | 131,093 | 129,424 | 139,188 |
| Common stock, 0.01 par value 400,000,000 shares authorized as of march 31, 2026 and december 31, 2025 158,656,318 shares and 156,182,177 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 1,913 | 1,888 | 1,793 | 1,783 |
| Additional paid-in capital | 3,104,838 | 3,062,715 | 2,846,278 | 2,820,404 |
| Accumulated other comprehensive income (loss) | -682 | 682 | 1,101 | 939 |
| Accumulated deficit | -2,179,971 | -2,051,524 | -1,922,975 | -1,796,073 |
| Total stockholders' equity | 926,098 | 1,013,761 | 926,197 | 1,027,053 |
| Total liabilities and stockholders equity | 1,266,023 | 1,144,854 | 1,055,621 | 1,166,241 |
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)